

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>In re United States Patent Application of:</b>	)	<b>Docket No.:</b>	<b>4115-178</b>
	)		
<b>Applicants:</b>	)	<b>Conf. No.:</b>	<b>4972</b>
	)		
<b>Application No.:</b>	)	<b>Art Unit:</b>	<b>1648</b>
	)		
<b>Date Filed:</b>	)	<b>Examiner:</b>	<b>Nicole Kinsey White</b>
	)		
<b>Title:</b>	)	<b>Customer No.:</b>	
	)		
	)		
	)		
	)		<b>23448</b>

**EFS CERTIFICATE**

I hereby certify that this document is being filed via EFS in the United States  
Patent and Trademark Office on March 2, 2008.

/ steven j. hultquist /

Steven J. Hultquist

**SUBMISSION OF AMENDMENTS AND SEQUENCE LISTING TO EFFECTUATE  
REVISIONS OF U.S. PATENT APPLICATION NO. 10/525,702 PROPOSED BY  
EXAMINER NICOLE KINSEY WHITE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In response to proposals made by Examiner Nicole Kinsey White to the undersigned attorney for amendments of this application that would place same in form for allowance, applicant hereby submits this response, amending the claims, submitting a sequence listing in compliance with the requirements of 37 CFR 1.821-1.825, for the SEQ ID NOS of the amended claim 21, amending the specification to incorporate by reference the SEQ ID NOS of such sequence listing, and submitting a Declaration under 37 C.F.R. § 1.132, attesting to the public availability, as of the filing date of the present application, of the nucleotide sequences identified in such sequence listing.

Amendments to the specification are set out in **Section I, Amendments to the Specification**, beginning on page 3 hereof, and amendments to the claims are set out in **Section II, Amendments to the Claims**, beginning on page 5 hereof.

Remarks concerning the substance of these amendments are set out in **Section III, Remarks**, beginning on page 10 hereof.

**THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.**